A clinical trial is currently assessing glycerol phenylbutyrate (Ravicti) in patients with GAT-1- and STXBP1-related developmental and epileptic encephalopathies (Grinspan et al., 2024). This evidence concerns the gene SLC6A1 and developmental and epileptic encephalopathy.